Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Proprietary Chinese Medicines

YICHANG, CHINA - JULY 18, 2023 - Citizens display purchased proprietary Chinese medicines in Yichang, Hubei province, China, July 18, 2023. The "2022 National Traditional Chinese Medicine Supervision Blue Book" issued under the guidance of the State Drug Administration was released. According to the blue book, a total of 47 varieties and 5,805 batches of proprietary Chinese medicines will be tested by the state in 2022, with a passing rate of 99.3%. According to the 2022 National Traditional Chinese Medicine Supervision Blue Book, as of May 2023, China has about 2,400 proprietary Chinese medicine manufacturers, with about 9,000 traditional Chinese medicine varieties and about 57,000 effective approval numbers, basically meeting the public's clinical drug needs.

E

Proprietary Chinese Medicines

YICHANG, CHINA - JULY 18, 2023 - Citizens display purchased proprietary Chinese medicines in Yichang, Hubei province, China, July 18, 2023. The "2022 National Traditional Chinese Medicine Supervision Blue Book" issued under the guidance of the State Drug Administration was released. According to the blue book, a total of 47 varieties and 5,805 batches of proprietary Chinese medicines will be tested by the state in 2022, with a passing rate of 99.3%. According to the 2022 National Traditional Chinese Medicine Supervision Blue Book, as of May 2023, China has about 2,400 proprietary Chinese medicine manufacturers, with about 9,000 traditional Chinese medicine varieties and about 57,000 effective approval numbers, basically meeting the public's clinical drug needs.

E

Proprietary Chinese Medicines

YICHANG, CHINA - JULY 18, 2023 - Citizens display purchased proprietary Chinese medicines in Yichang, Hubei province, China, July 18, 2023. The "2022 National Traditional Chinese Medicine Supervision Blue Book" issued under the guidance of the State Drug Administration was released. According to the blue book, a total of 47 varieties and 5,805 batches of proprietary Chinese medicines will be tested by the state in 2022, with a passing rate of 99.3%. According to the 2022 National Traditional Chinese Medicine Supervision Blue Book, as of May 2023, China has about 2,400 proprietary Chinese medicine manufacturers, with about 9,000 traditional Chinese medicine varieties and about 57,000 effective approval numbers, basically meeting the public's clinical drug needs.

E

Proprietary Chinese Medicines

YICHANG, CHINA - JULY 18, 2023 - Citizens display purchased proprietary Chinese medicines in Yichang, Hubei province, China, July 18, 2023. The "2022 National Traditional Chinese Medicine Supervision Blue Book" issued under the guidance of the State Drug Administration was released. According to the blue book, a total of 47 varieties and 5,805 batches of proprietary Chinese medicines will be tested by the state in 2022, with a passing rate of 99.3%. According to the 2022 National Traditional Chinese Medicine Supervision Blue Book, as of May 2023, China has about 2,400 proprietary Chinese medicine manufacturers, with about 9,000 traditional Chinese medicine varieties and about 57,000 effective approval numbers, basically meeting the public's clinical drug needs.

E

Proprietary Chinese Medicines

YICHANG, CHINA - JULY 18, 2023 - Citizens display purchased proprietary Chinese medicines in Yichang, Hubei province, China, July 18, 2023. The "2022 National Traditional Chinese Medicine Supervision Blue Book" issued under the guidance of the State Drug Administration was released. According to the blue book, a total of 47 varieties and 5,805 batches of proprietary Chinese medicines will be tested by the state in 2022, with a passing rate of 99.3%. According to the 2022 National Traditional Chinese Medicine Supervision Blue Book, as of May 2023, China has about 2,400 proprietary Chinese medicine manufacturers, with about 9,000 traditional Chinese medicine varieties and about 57,000 effective approval numbers, basically meeting the public's clinical drug needs.

E

Proprietary Chinese Medicines

YICHANG, CHINA - JULY 18, 2023 - Citizens display purchased proprietary Chinese medicines in Yichang, Hubei province, China, July 18, 2023. The "2022 National Traditional Chinese Medicine Supervision Blue Book" issued under the guidance of the State Drug Administration was released. According to the blue book, a total of 47 varieties and 5,805 batches of proprietary Chinese medicines will be tested by the state in 2022, with a passing rate of 99.3%. According to the 2022 National Traditional Chinese Medicine Supervision Blue Book, as of May 2023, China has about 2,400 proprietary Chinese medicine manufacturers, with about 9,000 traditional Chinese medicine varieties and about 57,000 effective approval numbers, basically meeting the public's clinical drug needs.

E

Proprietary Chinese Medicines

YICHANG, CHINA - JULY 18, 2023 - Citizens display purchased proprietary Chinese medicines in Yichang, Hubei province, China, July 18, 2023. The "2022 National Traditional Chinese Medicine Supervision Blue Book" issued under the guidance of the State Drug Administration was released. According to the blue book, a total of 47 varieties and 5,805 batches of proprietary Chinese medicines will be tested by the state in 2022, with a passing rate of 99.3%. According to the 2022 National Traditional Chinese Medicine Supervision Blue Book, as of May 2023, China has about 2,400 proprietary Chinese medicine manufacturers, with about 9,000 traditional Chinese medicine varieties and about 57,000 effective approval numbers, basically meeting the public's clinical drug needs.

E

Rakuten to launch e-book service July 19

TOKYO, Japan - Rakuten Inc. Chairman and Chief Executive Officer Hiroshi Mikitani holds Kobo Inc.'s proprietary Kobo Touch e-book reader during a press conference in Tokyo on July 2, 2012. Rakuten, a major Japanese online shopping mall operator, said it will launch an electronic book service in Japan on July 19 using Kobo, the Canadian e-book marketer it acquired in January.

E

Current Toshiba "SCiB" products

Toshiba is planning to commercialize the next generation of its proprietary SCiB lithium-ion rechargeable batteries in fiscal 2020 or later, with an energy density that is more than 50% higher than that of conventional products. The company has already developed a prototype cell at its research laboratory and will establish mass production technology. While SCiBs are strong in terms of longevity and fast charging performance, energy density, which leads to higher battery capacity, has been an issue. The company aims to expand its business by focusing on hybrid vehicles (HV), railroads and stationary applications. However, in the lithium-ion battery market as a whole, major manufacturers in Japan, China and South Korea are competing with each other. Toshiba's strategy is to target a "niche top" market by narrowing down the target market because price competition is not in Toshiba's favor. (Photo taken on November 15, 2019, credit: Nikkan Kogyo Shimbun / Kyodo News Images)

E

Mitsubishi Estate's Disaster Drill Using Robots

Mitsubishi Estate conducted a comprehensive disaster drill using security robots for foreign residents at several office buildings in Tokyo's Chiyoda Ward, including the Otemachi Park Building and Marunouchi Building. The robot is the SQ-2, which was jointly developed by the company and Seac Sense (Shibuya-ku, Tokyo), and is capable of autonomous driving. "How can I help you? and so on in English. SQ-2 is 1,300 millimeters tall, weighs 65 kilograms, and is equipped with a proprietary three-dimensional laser sensor, artificial intelligence (AI) functions, a high-resolution camera, and a fisheye camera. Mitsubishi Estate said, "We are increasing the number of English-speaking security guards due to the increase in inbound tourism and the holding of the Olympics, but there is a limit. We want to make up for it by using robots. (Photo taken on August 30, 2019, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)

E

John Mucha

Prague must prove its proprietary right to Czech Art Nouveau artist Alfons Mucha's Slav Epic paintings through acquisitive prescription, Prague 1 District Court ruled on January 8 ,2020, in Prague, Czech Republic, and adjourned the proceedings until April. In his lawsuit against the city, the painter's relative, John Mucha, pictured, claims that Prague never became the owner of the cycle of paintings since it did not fulfil the author's prerequisite of building a special exhibition space for them. Alfons Mucha (1860-1939) painted his Slav Epic cycle with motifs from the legends and more or less remote history of Slavonic nations in 1911-1928. The paintings' size ranges from about 4x5 to 6x8 metres. (CTK Photo/Katerina Sulova)

E

John Mucha

Prague must prove its proprietary right to Czech Art Nouveau artist Alfons Mucha's Slav Epic paintings through acquisitive prescription, Prague 1 District Court ruled on January 8 ,2020, in Prague, Czech Republic, and adjourned the proceedings until April. In his lawsuit against the city, the painter's relative, John Mucha, right, claims that Prague never became the owner of the cycle of paintings since it did not fulfil the author's prerequisite of building a special exhibition space for them. Alfons Mucha (1860-1939) painted his Slav Epic cycle with motifs from the legends and more or less remote history of Slavonic nations in 1911-1928. The paintings' size ranges from about 4x5 to 6x8 metres. (CTK Photo/Katerina Sulova)

E

John Mucha

Prague must prove its proprietary right to Czech Art Nouveau artist Alfons Mucha's Slav Epic paintings through acquisitive prescription, Prague 1 District Court ruled on January 8 ,2020, in Prague, Czech Republic, and adjourned the proceedings until April. In his lawsuit against the city, the painter's relative, John Mucha, center, claims that Prague never became the owner of the cycle of paintings since it did not fulfil the author's prerequisite of building a special exhibition space for them. Alfons Mucha (1860-1939) painted his Slav Epic cycle with motifs from the legends and more or less remote history of Slavonic nations in 1911-1928. The paintings' size ranges from about 4x5 to 6x8 metres. On the right side is seen John Mucha's advocate Frantisek Vyskocil. (CTK Photo/Katerina Sulova)

E

John Mucha

Prague must prove its proprietary right to Czech Art Nouveau artist Alfons Mucha's Slav Epic paintings through acquisitive prescription, Prague 1 District Court ruled on January 8 ,2020, in Prague, Czech Republic, and adjourned the proceedings until April. In his lawsuit against the city, the painter's relative, John Mucha, pictured, claims that Prague never became the owner of the cycle of paintings since it did not fulfil the author's prerequisite of building a special exhibition space for them. Alfons Mucha (1860-1939) painted his Slav Epic cycle with motifs from the legends and more or less remote history of Slavonic nations in 1911-1928. The paintings' size ranges from about 4x5 to 6x8 metres. (CTK Photo/Katerina Sulova)

E

John Mucha

Prague must prove its proprietary right to Czech Art Nouveau artist Alfons Mucha's Slav Epic paintings through acquisitive prescription, Prague 1 District Court ruled on January 8 ,2020, in Prague, Czech Republic, and adjourned the proceedings until April. In his lawsuit against the city, the painter's relative, John Mucha, pictured, claims that Prague never became the owner of the cycle of paintings since it did not fulfil the author's prerequisite of building a special exhibition space for them. Alfons Mucha (1860-1939) painted his Slav Epic cycle with motifs from the legends and more or less remote history of Slavonic nations in 1911-1928. The paintings' size ranges from about 4x5 to 6x8 metres. (CTK Photo/Katerina Sulova)

E

John Mucha

Prague must prove its proprietary right to Czech Art Nouveau artist Alfons Mucha's Slav Epic paintings through acquisitive prescription, Prague 1 District Court ruled on January 8 ,2020, in Prague, Czech Republic, and adjourned the proceedings until April. In his lawsuit against the city, the painter's relative, John Mucha, right, claims that Prague never became the owner of the cycle of paintings since it did not fulfil the author's prerequisite of building a special exhibition space for them. Alfons Mucha (1860-1939) painted his Slav Epic cycle with motifs from the legends and more or less remote history of Slavonic nations in 1911-1928. The paintings' size ranges from about 4x5 to 6x8 metres. On the left side is seen John Mucha's advocate Frantisek Vyskocil. (CTK Photo/Katerina Sulova)

E

John Mucha

Prague must prove its proprietary right to Czech Art Nouveau artist Alfons Mucha's Slav Epic paintings through acquisitive prescription, Prague 1 District Court ruled on January 8 ,2020, in Prague, Czech Republic, and adjourned the proceedings until April. In his lawsuit against the city, the painter's relative, John Mucha, pictured, claims that Prague never became the owner of the cycle of paintings since it did not fulfil the author's prerequisite of building a special exhibition space for them. Alfons Mucha (1860-1939) painted his Slav Epic cycle with motifs from the legends and more or less remote history of Slavonic nations in 1911-1928. The paintings' size ranges from about 4x5 to 6x8 metres. (CTK Photo/Katerina Sulova)

E

John Mucha

Prague must prove its proprietary right to Czech Art Nouveau artist Alfons Mucha's Slav Epic paintings through acquisitive prescription, Prague 1 District Court ruled on January 8 ,2020, in Prague, Czech Republic, and adjourned the proceedings until April. In his lawsuit against the city, the painter's relative, John Mucha, center, claims that Prague never became the owner of the cycle of paintings since it did not fulfil the author's prerequisite of building a special exhibition space for them. Alfons Mucha (1860-1939) painted his Slav Epic cycle with motifs from the legends and more or less remote history of Slavonic nations in 1911-1928. The paintings' size ranges from about 4x5 to 6x8 metres. On the left side is seen John Mucha's advocate Frantisek Vyskocil. (CTK Photo/Katerina Sulova)